Scott Rocklage has a vast experience of up to three decades in healthcare management experience coupled with strategic leadership responsibilities. He has been Chair and CEO of Cubist Pharmaceuticals, CEO and President of Nycomed Salutar, and also served in the positions of R&D at Salutar and Catalytica. He formerly served as Chairman of the Board at Novira and Relypsa (NASDAQ:RYLP). Presently, he sits on the board of Pulmatrix (NASDAQ:PULMA); Rennovia, Kinestral, and Cidara; as well as Epirus (NASDAQ:EPRS). Dr. Scott attended the University of California and received his B.Sc. in Chemistry, and MIT where he earned his Ph.D. in Chemistry. He is an inventor, and co-inventor of more than 30 patents and has over 100 publications.
In 2003, Scott joined the 5AM Ventures and later on, in 2004, went on to become a managing partner. Since 1994, Scott was the Chief Executive Officer to the Cubist Pharmaceuticals and oversaw development and approval of Cubicin (a new antibiotic treatment) by the FDA. Before joining Cubist, Dr. Scott had managed the development of other two pharmaceutical products that were approved by the FDA. At then, he acted as the CEO of the Nycomed Salutar, Inc.
When Scott joined 5AM Ventures, he was in a team of three other investment professionals who had founded the 5AM Ventures from Bay City Capital in 2002. Within the first year, the firm invested in six biotech companies: Celscia Therapeutics, Miikana Therapeutics, Kalypsys, Symyx Therapeutics, Ambrx, and Alexza. The managing partner, and founder of the 5AM Ventures, John Diekman, Ph.D., was very proud of the addition of Scott, especially in their early stage investment team. He was full of praise for Scott for having successfully overseen the authorization of three US NDAs, involvement in the building of infrastructure to help in drug launches, and for establishing secure pipelines to cater for development. Diekman believes that the successful operational experience of Scott would be of significant value addition to their existing, and future companies. Scott was made the Executive Chairman of the Miikana Therapeutics, and they were already finalizing on putting him in another similar position in another portfolio firm.
Scott Rocklage, having known the founder of the 5AM for over 15 years, expressed his excitement in joining such a proficient team of entrepreneurs, and investors. He said that he was looking forward to making significant contributions based on his experience to help in the advancement of the 5AM’s portfolio of inspiring and innovative biotechnology ventures. Scott Rocklage has been able to lead teams raising more than $500 million, including the IPO of Cubist Pharmaceutical and several other successful follow-on financings.
About 5AM Ventures
5AM Ventures is a leading early-stage fund that is focused on coming up and building companies that are based in biotechnology. The Ventures support firms working to solve essential healthcare needs through cutting-edge discoveries in science and medicine.